CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $609.12B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 4.14: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.12%Below 5Y avg (2.77%)
Annual Rate
USD 5.36Paid quarterly
Payout Ratio
60.8%Moderate
Consecutive Growth
19 yrStrong track record
Paying Dividends
26 yr
Payback Period
51.6 yr
Next Ex-Dividend
Aug 25, 2026
Last Payment
Jun 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
609.12BUSDvs all stocks (USD)
Trailing P/E
29.32xRevenue (TTM)
97.93BUSDvs all stocks (USD)
Profit Margin
21.48%Beta
0.2350xvs all stocks
52-Week Change
53.96%vs all stocks
Forward Annual Dividend Yield
2.12%vs all stocks
Market Capitalization
609.12BUSDvs all stocks (USD)
Enterprise Value
642.06BUSDvs all stocks (USD)
Trailing P/E
29.32xForward P/E
19.73xPrice to Sales (TTM)
6.22xPrice to Book (MRQ)
7.50xEnterprise to Revenue
6.56xEnterprise to EBITDA
18.43xProfit Margin
21.48%Operating Margin
28.61%Return on Assets (TTM)
13.46%Return on Equity (TTM)
32.87%Revenue (TTM)
97.93BUSDvs all stocks (USD)
Revenue per Share (TTM)
40.51USDUpdated Jul 19, 2026Quarterly Revenue Growth
6.60%Gross Profit (TTM)
66.69BUSDvs all stocks (USD)
EBITDA (TTM)
35.16BUSDvs all stocks (USD)
Net Income (TTM)
21.04BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-0.10%Operating Cash Flow (TTM)
22.21BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
43.47BUSDvs all stocks (USD)
Forward Annual Dividend Rate
5.36USDUpdated Jul 19, 2026Forward Annual Dividend Yield
2.12%vs all stocks
Trailing Annual Dividend Rate
5.24USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
2.07%vs all stocks
5-Year Average Dividend Yield
2.77%vs all stocks
Payout Ratio
60.79%Revenue
94.19BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
30.26BUSDFY2025 · Dec 31, 2025Gross Profit
63.94BUSDFY2025 · Dec 31, 2025Operating Income
25.60BUSDvs all stocks (USD)
Pre-tax Income
32.58BUSDFY2025 · Dec 31, 2025Income Tax Expense
5.78BUSDFY2025 · Dec 31, 2025Net Income
26.80BUSDFY2025 · Dec 31, 2025EBIT
33.55BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
35.16BUSDFY2025 · Dec 31, 2025Research & Development
14.66BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.68BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.06BUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
971.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
11.13USDFY2025 · Dec 31, 2025EPS (Diluted)
11.03USDFY2025 · Dec 31, 2025Basic Shares Outstanding
2.41BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.41BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
26.80BUSDFY2025 · Dec 31, 2025Operating Cash Flow
22.21BUSDFY2025 · Dec 31, 2025Free Cash Flow
17.38BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
19.71BUSDFY2025 · Dec 31, 2025Income Tax Paid
6.54BUSDFY2025 · Dec 31, 2025Interest Paid
1.98BUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
26.80BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
7.50BUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
1.54BUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.35BUSDFY2025 · Dec 31, 2025Other Non-cash Items
109.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.78BUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-13.31BUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.83BUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-385.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
-17.54BUSDFY2025 · Dec 31, 2025Purchase of Investments
-920.00MUSDFY2025 · Dec 31, 2025Sale of Investments
1.66BUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.57BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-23.20BUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
9.14BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-14.09BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
2.26BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-5.95BUSDFY2025 · Dec 31, 2025Common Dividends Paid
-12.38BUSDFY2025 · Dec 31, 2025Other Financing Charges
-260.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-21.29BUSDFY2025 · Dec 31, 2025Shares Outstanding
2.41BSharesUpdated Jul 19, 2026Float Shares
2.40BSharesUpdated Jul 19, 2026Shares Short
26.58MSharesUpdated Jul 19, 2026Short Ratio
2.96daysvs all stocks
Short % of Shares Outstanding
1.23%vs all stocks
% Held by Insiders
0.05%vs all stocks
% Held by Institutions
76.88%vs all stocks
Total Cash (MRQ)
22.05BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.16USDUpdated Jul 19, 2026Total Debt (MRQ)
54.99BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6773xCurrent Ratio (MRQ)
1.03xBook Value per Share (MRQ)
33.73USDUpdated Jul 19, 2026Total Assets
199.21BUSDvs all stocks (USD)
Total Current Assets
55.62BUSDFY2025 · Dec 31, 2025Total Liabilities
117.67BUSDFY2025 · Dec 31, 2025Total Non-current Assets
143.59BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
63.54BUSDFY2025 · Dec 31, 2025Total Current Liabilities
54.13BUSDFY2025 · Dec 31, 2025Cash
3.30BUSDFY2025 · Dec 31, 2025Cash Equivalents
16.41BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
19.71BUSDFY2025 · Dec 31, 2025Other Short-term Investments
393.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
17.18BUSDFY2025 · Dec 31, 2025Inventory
14.19BUSDFY2025 · Dec 31, 2025Accounts Payable
11.99BUSDFY2025 · Dec 31, 2025Short-term Debt
8.49BUSDFY2025 · Dec 31, 2025Long-term Debt
39.44BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
9.87BUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.12BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
81.54BUSDvs all stocks (USD)
Treasury Stock
75.62BUSDFY2025 · Dec 31, 202552-Week Low
162.78USDUpdated Jul 19, 202652-Week High
269.43USDUpdated Jul 19, 202652-Week Change
53.96%vs all stocks
Beta
0.2350xvs all stocks
50-Day MA
238.66USDUpdated Jul 19, 2026200-Day MA
222.92USDUpdated Jul 19, 2026Avg 10-Day Volume
8.15MSharesUpdated Jul 19, 2026Avg 30-Day Volume
8.81MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
8.63USDUpdated Jul 19, 2026Other Income / Expense
6.89BUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.14: safe zoneNotable
Altman Z-Score: 4.14
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $609.12B, higher than 95% of all stocks globallySignificant
Market cap (USD): 609,122,165,491Global P95: 25,614,208,870.135
Revenue is $97.93B, higher than 95% of all stocks globallySignificant
Revenue (USD): 97,929,003,008Global P95: 14,667,937,174.886
Levered free cash flow is $43.47B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 43,470,000,000Global P95: 1,123,592,359.78
Companies that share the same coordination system — how they create, deliver, or capture value.
AbbVie Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eli Lilly and Company
Tier 1ProductionApproval-Gated PipelineRuleRisk
Roche Holding AG Genussscheine
Tier 1ProductionApproval-Gated PipelineRuleRisk
Merck & Co., Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Novartis AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
AstraZeneca PLC
Tier 1ProductionApproval-Gated PipelineRuleFlow
Amgen Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abbott Laboratories
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gilead Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novo Nordisk A/S
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Eclerx Services Ltd.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Endurance Technologies Ltd.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Eris Lifesciences Ltd.
1 interpretationMulti-Year Revenue, Profit, And Income Growth